HomeCompareIBXXF vs CL

IBXXF vs CL: Dividend Comparison 2026

IBXXF yields 17857.14% · CL yields 2.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IBXXF wins by $17047106584171659264.00M in total portfolio value
10 years
IBXXF
IBXXF
● Live price
17857.14%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$17047106584171659264.00M
Annual income
$16,861,361,028,467,424,000,000,000.00
Full IBXXF calculator →
CL
CL
● Live price
2.44%
Share price
$85.23
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.0K
Annual income
$5,451.69
Full CL calculator →

Portfolio growth — IBXXF vs CL

📍 IBXXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIBXXFCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IBXXF + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IBXXF pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IBXXF
Annual income on $10K today (after 15% tax)
$1,517,857.14/yr
After 10yr DRIP, annual income (after tax)
$14,332,156,874,197,310,000,000,000.00/yr
CL
Annual income on $10K today (after 15% tax)
$207.44/yr
After 10yr DRIP, annual income (after tax)
$4,633.94/yr
At 15% tax rate, IBXXF beats the other by $14,332,156,874,197,310,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IBXXF + CL for your $10,000?

IBXXF: 50%CL: 50%
100% CL50/50100% IBXXF
Portfolio after 10yr
$8523553292085829632.00M
Annual income
$8,430,680,514,233,712,000,000,000.00/yr
Blended yield
98.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

IBXXF
No analyst data
Altman Z
-55.2
Piotroski
4/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+8.5% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IBXXF buys
0
CL buys
0
No recent congressional trades found for IBXXF or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIBXXFCL
Forward yield17857.14%2.44%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$17047106584171659264.00M$41.0K
Annual income after 10y$16,861,361,028,467,424,000,000,000.00$5,451.69
Total dividends collected$17034838237245739008.00M$18.1K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: IBXXF vs CL ($10,000, DRIP)

YearIBXXF PortfolioIBXXF Income/yrCL PortfolioCL Income/yrGap
1← crossover$1,796,414$1,785,714.29$11,014$313.84+$1.79MIBXXF
2$301,724,280$299,802,117.11$12,200$415.44+$301.71MIBXXF
3$47,383,143,508$47,060,298,527.98$13,607$553.09+$47383.13MIBXXF
4$6,957,621,293,196$6,906,921,329,642.40$15,301$741.41+$6957621.28MIBXXF
5$955,290,364,037,133$947,845,709,253,412.80$17,374$1,002.00+$955290364.02MIBXXF
6$122,648,736,931,019,340$121,626,576,241,499,600.00$19,958$1,367.44+$122648736931.00MIBXXF
7$14,725,168,454,748,666,000$14,593,934,306,232,474,000.00$23,243$1,887.87+$14725168454748.64MIBXXF
8$1,653,272,868,532,626,000,000$1,637,516,938,286,045,300,000.00$27,512$2,642.43+$1653272868532626.25MIBXXF
9$173,593,977,293,677,440,000,000$171,824,975,324,347,530,000,000.00$33,197$3,759.22+$173593977293677440.00MIBXXF
10$17,047,106,584,171,660,000,000,000$16,861,361,028,467,424,000,000,000.00$40,973$5,451.69+$17047106584171659264.00MIBXXF

IBXXF vs CL: Complete Analysis 2026

IBXXFStock

Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the combined technologies for enhancing brain tumor imaging and diagnosis; and a joint development agreement with Global Cancer Technology, Inc. to develop GCT's novel nanoscintillator technology for the treatment of breast cancer. The company was incorporated in 2016 and is based in San Diego, California.

Full IBXXF Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this IBXXF vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IBXXF vs SCHDIBXXF vs JEPIIBXXF vs OIBXXF vs KOIBXXF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.